On this page you will find useful information regarding which patients should be initiated on UPTRAVI®, guidance on prescribing and administering UPTRAVI®, access to the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines and 2018 World Symposium on Pulmonary Hypertension (WSPH) proceedings, and recommendations for screening and diagnosing patients with systemic sclerosis (SSc) or congenital heart disease (CHD) and suspected pulmonary arterial hypertension (PAH).
Prescribing UPTRAVI®
Guidance on correctly starting your patient on their UPTRAVI® journey.
PAH guidelines and organisations
Identifying PAH in patients with SSc
Learn how PAH can impact patients with scleroderma.
Learn about the investigation and referral pathways for patients with SSc and suspected PAH.
Identifying PAH in patients with CHD
Learn how PAH can impact patients with CHD.
Learn about the investigation and referral pathways for patients with CHD and suspected PAH.
Learn More About UPTRAVI®
Studies
Details of the GRIPHON study, where the safety and efficacy of UPTRAVI® were investigated in a Phase 3 study to assess the long-term benefits for pulmonary arterial hypertension (PAH) patients.
Product Overview
A synopsis of the key benefits of UPTRAVI® in the treatment of PAH.
